One company, six parts

People ask why 199 is six parts — discovery, manufacturing, diagnostics, clinic, clinical tech, gene therapy — when most biotech founders would pick one, bet on it, and stay in their lane.

The honest answer is that the lane is useful for financing, but the patient does not experience the lane. A patient experiences a compound that has to be discovered, manufactured to a standard, dosed based on some measurement of their biology, and delivered in a clinical setting. If any one of those breaks, the therapy does not reach them. When I looked at what was broken in longevity, it was not any one of those pieces — it was the seams between them.

So we own the seams. 199 Biotechnologies runs discovery. 199 Labs manufactures. 199 Diagnostics measures. 199 Clinic delivers. Triple Helix handles gene-therapy vectors. Every part exists so that the adjacent parts have a partner who will not drop the baton.

This is not a cheap architecture. It does mean that when we want to run a senolytic trial, we do not have to negotiate with a CMO, an external diagnostic vendor, and an unfamiliar clinic. That is the whole point.